Premium
The horizontal development of cell‐mediated tumor‐specific immunity in rous sarcoma virus tumorigenesis in rats
Author(s) -
Jonsson Nils
Publication year - 1973
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910120117
Subject(s) - rous sarcoma virus , immunity , latency stage , biology , immune system , inoculation , virus , cellular immunity , humoral immunity , immunology , lymph node , virology , sarcoma , pathology , medicine
The horizontal development of lymphoid cell‐mediated specific antitumor immunity was studied in R/F rats, inoculated with the Schmidt‐Ruppin strain of Rous sarcoma virus (SR‐RSV) during the neonatal period. Lymph‐node cells (LNC) were harvested from individual animals on consecutive occasions and used in colony inhibition tests for the detection of LNC‐mediated immunity to the Rous‐specific tumor‐associated transplantation antigen (s). None of the rats tested, which had been SR‐RSV inoculated within 6 days after birth, had any demonstrable LNC‐mediated immunity when tested within 4 weeks after virus inoculation. At the same time 68% of the rats SR‐RSV‐inoculated at a higher age disclosed a clear‐cut immunity. In the former group sarcomas appeared after short latency periods (average 5 weeks), while the latter group developed sarcomas with long latency periods (average 11 weeks) or remained tumor‐free. Also in tests performed later after SR‐RSV‐inoculation rats remaining tumor‐free or developing very late tumors tended to develop an LNC‐mediated immunity more rapidly than rats with tumors appearing earlier. The majority of both tumor‐positive and tumor‐negative animals developed at some time an LNC‐mediated immunity, which often persisted for several months in negative animals but sometimes disappeared in rats with a large tumor burden. The results indicate that the kinetics of the LNC‐mediated antitumor immune response can be of importance for the development of primary Rous sarcomas.